Syndax Announces Participation at Two Upcoming Investor Conferences

On February 28, 2022 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that members of its management team will participate in two upcoming investor conferences (Press release, Syndax, FEB 28, 2022, View Source [SID1234609151]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A panel at the Cowen 42nd Annual Health Care Conference at 10:30 a.m. ET on Monday, March 7, 2022.
A presentation followed by a fireside chat at the Barclays Global Healthcare Conference at 3:50 p.m. ET on Wednesday, March 16, 2022.
A live webcast of the Cowen panel and Barclays presentation can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the events will also be available for a limited time.